Latest news with #2025CDMOLeadershipAwards
Cision Canada
05-05-2025
- Business
- Cision Canada
/C O R R E C T I O N -- Suanfarma/ English
In the news release, Pere Mañé Appointed as New CEO of Suanfarma, issued April 22, 2025 by Suanfarma over PR Newswire, we are advised by the company that the award mentioned in the 3rd paragraph should read "2025 CDMO Leadership Awards" rather than as originally issued inadvertently. The complete, corrected release follows: Pere Mañé Appointed as New CEO of Suanfarma MADRID, April 22, 2025 /CNW/ -- Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ingredients (APIs) and high-value CDMO services for the health industry, has announced the appointment of Pere Mañé Godina as its new Chief Executive Officer (CEO). This marks the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion. With a career spanning more than 30 years, Pere has held technical and strategic executive positions at leading pharmaceutical companies such as Uquifa, Boehringer Ingelheim, and Esteve Química (Esteve Group). His experience ranges from technical and operational roles to executive positions such as General Manager and Group Chief Industrial Operations Officer. Most recently, Pere played a key role in the industrial transformation of Esteve, positioning its chemical division as a global benchmark. Under his leadership, the company was recognized as CDMO of the Year – Small Molecules at the 2025 CDMO Leadership Awards, one of the industry's most prestigious honors. This appointment aligns with Suanfarma's long-term strategic vision. Carlos Alonso, interim CEO since October 2024, will ensure a smooth transition and will remain with the company as Executive Chairman: "We are confident that Pere's deep sector knowledge, strategic mindset, and leadership experience will be instrumental in strengthening Suanfarma's market position and continuing to deliver high-value solutions to our customers and partners." Pere's arrival brings decisive momentum to Suanfarma's growth journey. His focus on operational excellence, advanced CDMO capabilities, and strong strategic partnerships will guide the company through its next phase with the following objectives: Streamlining industrial operations and integrating new technologies Strengthening relationships with global clients and key suppliers Accelerating international expansion Fostering a culture of innovation and sustainability In the words of Pere Mañé Godina, "Suanfarma has all the elements to lead the future of the industry: a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team. I'm excited to begin this new chapter and work together to keep delivering innovative, efficient, and sustainable solutions to our clients." Founded in 1993, Suanfarma is a B2B partner in the life sciences sector, committed to health and innovation through the sustainable development, manufacturing, and distribution of high-quality pharmaceutical ingredients. With presence in over 70 countries, it has been part of the healthcare-focused investment firm Archimed since 2021.
Yahoo
21-03-2025
- Business
- Yahoo
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards. The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global biopharma and biotechnology companies. The awards use feedback exclusively from experienced industry leaders to evaluate CDMOs across key performance metrics. OXB's recognition reflects the Company's excellence in quality, innovation and service capabilities across its integrated global network of facilities, and highlights its growing position as a world-leading cell and gene therapy CDMO. Dr. Sebastien Ribault, Chief Business Officer of OXB, said: "We are honoured to receive this recognition which validates our successful transformation into a pure-play cell and gene therapy CDMO. This award reflects both our 30-year heritage of innovation in viral vectors and the success of our 'One OXB' multi-vector, multi-site strategy across the UK, US and France. Most importantly, it acknowledges our team's commitment to quality and collaboration as we work alongside our clients to enable the delivery of life-changing therapies to patients worldwide." This industry recognition coincides with a period of strong commercial momentum for OXB, with growing demand for its CDMO services across all key viral vector types and an expanding global client portfolio spanning multiple development stages from early clinical work through to commercialisation. -Ends- Enquiries: OXB: Sebastien Ribault, Chief Business Officer – T: +44 (0) 1865 783 000 / E: partnering@ ICR Healthcare:T: +44 (0)20 3709 5700 / E: oxb@ Mary-Jane Elliott / Angela Gray / Davide Salvi About OXB OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at and follow us on LinkedIn and in to access your portfolio
